ArticleCancers2021
Unexpected Benefits of Multiport Synchrotron Microbeam Radiation Therapy for Brain Tumors.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Article
- Article
- Application of Synchrotron Radiation in Fundamental Research and Clinical Medicine.Biomedicines · 2025Review
- Time-lapse imaging of cells in spatially fractionated X-ray fields using a mini beam as an alternative to accelerator-based sub-millimeter beams.Journal of radiation research · 2025Article
- The Combination of Temporal and Spatial Dose Fractionation in Microbeam Radiation Therapy.Biomedicines · 2025Article
- The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model.Advances in radiation oncology · 2025Article
- Advancements and challenges in brain cancer therapeutics.Exploration (Beijing, China) · 2024Review
- Article
- Treatment planning with high-resolution 3D dose maps in preclinical and translational synchrotron microbeam radiation therapy.Physics and imaging in radiation oncology · 2024Article
- Immune Priming with Spatially Fractionated Radiation Therapy.Current oncology reports · 2023Review
- Monocrystalline diamond detector for online monitoring during synchrotron microbeam radiotherapy.Journal of synchrotron radiation · 2023Article
- MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.Journal of synchrotron radiation · 2023Article
- Microbeam Irradiation as a Simultaneously Integrated Boost in a Conventional Whole-Brain Radiotherapy Protocol.International journal of molecular sciences · 2022Article
- Should Peak Dose Be Used to Prescribe Spatially Fractionated Radiation Therapy?-A Review of Preclinical Studies.Cancers · 2022Review
- A high-resolution dose calculation engine for X-ray microbeams radiation therapy.Medical physics · 2022Article
- Targeted Accumulation of Macrophages Induced by Microbeam Irradiation in a Tissue-Dependent Manner.Biomedicines · 2022Article
- Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.International journal of molecular sciences · 2022Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivery of high-radiation doses to brain tumors via multiple arrays of synchrotron X-ray microbeams permits huge therapeutic advantages. Brain tumor (9LGS)-bearing and normal rats were irradiated using a conventional, homogeneous Broad Beam (BB), or Microbeam Radiation Therapy (MRT), then studied by behavioral tests, MRI, and histopathology. A valley dose of 10 Gy deposited between microbeams, delivered by a single port, improved tumor control and median survival time of tumor-bearing rats better than a BB isodose. An increased number of ports and an accumulated valley dose maintained at 10 Gy delayed tumor growth and improved survival. Histopathologically, cell death, vascular damage, and inflammatory response increased in tumors. At identical valley isodose, each additional MRT port extended survival, resulting in an exponential correlation between port numbers and animal lifespan (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.